{"organizations": [], "uuid": "5dee47aea2f410ae76b10b8ed7a3aef411fae039", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180402.html", "section_title": "Archive News &amp; Video for Monday, 02 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rhythm-pharma-announces-licensing/brief-rhythm-pharma-announces-licensing-agreement-with-takeda-idUSFWN1RF09H", "country": "US", "domain_rank": 408, "title": "BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T20:40:00.000+03:00", "replies_count": 0, "uuid": "5dee47aea2f410ae76b10b8ed7a3aef411fae039"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rhythm-pharma-announces-licensing/brief-rhythm-pharma-announces-licensing-agreement-with-takeda-idUSFWN1RF09H", "ord_in_thread": 0, "title": "BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rhythm pharmaceuticals inc", "sentiment": "negative"}, {"name": "takeda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2 (Reuters) - Rhythm Pharmaceuticals Inc:\n* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME\n* RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​\n* RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​\n* RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​\n* RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO’S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​\n* RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-02T20:40:00.000+03:00", "crawled": "2018-04-03T16:19:28.000+03:00", "highlightTitle": ""}